Nanox generated revenue of $2.7M in Q2 2024, a slight increase from $2.6M in Q2 2023, while net loss decreased to $13.6M from $17.4M YoY. The company advanced its US deployment program with Nanox.ARC systems installed in seven states and secured installations with three chain medical imaging providers.The company submitted a new 510k application to FDA to expand Nanox.ARC's intended use for general purposes including chest imaging. Additionally, Nanox.AI received FDA 510K clearance for HealthCCSng V2.0, an upgraded cardiac solution that introduces 'zero calcium' categorization and exact calcium score detection.As of June 30, 2024, Nanox maintained a strong financial position with $64.2M in cash, cash equivalents, restricted deposits and marketable securities. The company's operating expenses decreased, with R&D expenses down $2.1M and general and administrative expenses reduced by $1.7M compared to Q2 2023.

Nanox generated revenue of $2.7M in Q2 2024, a slight increase from $2.6M in Q2 2023, while net loss decreased to $13.6M from $17.4M YoY. The company advanced its US deployment program with Nanox.ARC systems installed in seven states and secured installations with three chain medical imaging providers.The company submitted a new 510k application to FDA to expand Nanox.ARC's intended use for general purposes including chest imaging. Additionally, Nanox.AI received FDA 510K clearance for HealthCCSng V2.0, an upgraded cardiac solution that introduces 'zero calcium' categorization and exact calcium score detection.As of June 30, 2024, Nanox maintained a strong financial position with $64.2M in cash, cash equivalents, restricted deposits and marketable securities. The company's operating expenses decreased, with R&D expenses down $2.1M and general and administrative expenses reduced by $1.7M compared to Q2 2023.